What question did this study set out to answer?

This study aims to assess treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer after progressing on first-line endocrine therapy with CDK4/6 inhibitors.

February 19, 2026Clinical Cancer Research

Abstract PS2-02-20: Treatment patterns and clinical outcomes following progression on first-line ET + CDK4/6i among patients with HR+/HER2− metastatic breast cancer (mBC) in the US

View Full Paper

Ask AI

Bookmark

Authors

VKV. KaklamaniThe University of Texas Health Science Center at San Antonio SVSamantha ValliantDaiichi Sankyo (United States)SHShannon HunterDaiichi Sankyo (India)

Discussion

Member takes

Implication

This observational cohort study examines treatment patterns and outcomes following progression in HR+/HER2− metastatic breast cancer, indicating the need for better therapies.

Key Points

This study aims to assess treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer after progressing on first-line endocrine therapy with CDK4/6 inhibitors.
Retrospective observational cohort study
Utilized US-based Flatiron Health Enhanced Datamart
Included adult patients with HR+/HER2− mBC who progressed on 1L treatment between Jan 2017 and Sep 2024
Evaluated treatment data and demographics descriptively
Analyzed primary and secondary endpoints using Kaplan-Meier methods.
1415 patients included with a median age of 65 years.
57.3% experienced progression within 12 months of first-line treatment.
63.6% received an endocrine therapy-based regimen in second-line treatment.
Median progression-free survival on second-line treatments ranged from 4 to 8 months.
Overall survival in second-line treatments ranged from 14 to 32 months.

Cite This Study

Kaklamani et al. (2026) studied this question.

synapsesocial.com/papers/6996a8b5ecb39a600b3efc65 https://doi.org/10.1158/1557-3265.sabcs25-ps2-02-20

View Full Paper

Ask AI

Bookmark

Implication

This observational cohort study examines treatment patterns and outcomes following progression in HR+/HER2− metastatic breast cancer, indicating the need for better therapies.

Abstract PS2-02-20: Treatment patterns and clinical outcomes following progression on first-line ET + CDK4/6i among patients with HR+/HER2− metastatic breast cancer (mBC) in the US

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS2-02-20: Treatment patterns and clinical outcomes following progression on first-line ET + CDK4/6i among patients with HR+/HER2− metastatic breast cancer (mBC) in the US

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider